Impact of Dapaglizofin on right ventricular function and pulmonary pressure: a secondary analysis of the RIVED registry

11 May 2026 (16:19 - 16:27)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Associate Professor Alberto Palazzuoli

University of Siena, Siena (Italy)

5 More presentations in this session

Presentation thumbnail

Association of poor adherence to guideline-directed medical treatment with adverse events including fatal arrhythmia in heart failure with reduced ejection fraction: A nationwide cohort analysis

Doctor M. Kim (Goyang, KR)

Abstract Slides Video

Presentation thumbnail

Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial

Doctor P. Haller (Vienna, AT)

Abstract Slides Video

Presentation thumbnail

Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure

Doctor A. Castro Pinto (Guimaraes, PT)

Abstract Slides Video

Presentation thumbnail

The O-GlcNAcase inhibitor ASN90 opposes acute cardiac decompensation in rats with chronic heart failure.

Doctor G. Vincent (Rouen, FR)

Presentation thumbnail

Potentially inappropriate medications in older adults with heart failure: prevalence and predictors using the 2023 Beers Criteria

Doctor M. Sheikh-Taha (Blat, LB)

Abstract Slides Video

Access the full session

Session thumbnail

Medical treatment in acute heart failure

The Event

Event poster

Heart Failure 2026

11 May 2026 16:19 CET

You may be interested in

Congress Presentation

The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized empire hf clinical trial

Congress Session

Further Insights into SGLT2i treatment for heart failure

Congress Session

Medical treatment in acute heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources